Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Lymphoma Patients

High dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplant (AHSCT) is the standard of care in first-line treatment for eligible mantle cell and most T-cell Non-Hodgkin lymphoma (NHL) and in primary refractory or relapse NHL [1 –3]. Over the last two decade transplant programs have seen a significant increase in the median age of AHSCT recipients [7]. Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) revealed that the percentage of AHSCT in patients ≥ 60 years old has increased from 1 0% between 2000-2006 to 22% between 2007-2015.

Source: Biology of Blood and Marrow Transplantation - September 11, 2019 Category: Hematology Authors: Christopher Lemieux, Imran Ahmad, Nadia M. Bambace, L éa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Isabelle Fleury, Thomas Kiss, Luigina Mollica, Denis-Claude Roy, Guy Sauvageau, Jean Roy, Silvy Lachance Source Type: research